Benchling IPO
Benchling is a cloud R&D platform built for life sciences companies to manage experiments, samples, molecular biology workflows, and research data. The company is used by major biotech and pharmaceutical companies including Moderna, Regeneron, and Gilead. Benchling is valued at around $6.1 billion and is a strong candidate for a life sciences software IPO.
What We Know
Benchling is valued at around $6.1 billion and serves major biotech and pharmaceutical companies including Moderna and Regeneron. The company has not announced IPO plans. Benchling is considered a strong candidate for a life sciences software IPO when market conditions improve.
Frequently Asked Questions
Has Benchling had an IPO?
As of early 2026, Benchling has not announced any plans to go public. The company remains private with no confirmed IPO filing or timeline. Sign up for alerts to get notified if Benchling announces an IPO.
When is the Benchling IPO date?
There is no Benchling IPO date because the company has not announced plans to go public. An IPO could happen in the future, but no timeline has been shared. Sign up for alerts to be notified of any updates.
How can I buy Benchling stock?
Benchling is currently a private company with no announced IPO. If the company does go public in the future, you'll be able to buy shares through any major brokerage. Sign up for alerts to stay informed.
Stay Updated on the Benchling IPO
Get real-time alerts when Benchling files for an IPO, prices shares, or begins trading.
Get IPO Alerts